Literature DB >> 11781222

Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity.

Thomas J Raife1, Steven R Lentz, Bonnie S Atkinson, Sara K Vesely, Martin J Hessner.   

Abstract

Thrombotic microangiopathy (TM) is associated with abnormalities of von Willebrand factor-cleaving protease (VWCP) and other hemostatic factors. This study hypothesized that TM patients might have genetically determined thrombotic risk factors that predispose them to aberrant microvascular thrombosis. DNA samples from 30 white and 12 African American adult TM patients were analyzed for genetic alleles associated with vascular thrombosis, and plasma samples were analyzed for levels of VWCP activity. DNA was analyzed by using allele-specific polymerase chain reaction for factor V 1691A (Leiden), factor II 20 210A, methylenetetrahydrofolate reductase 667T, type 1 plasminogen activator inhibitor 4G/5G, and platelet GPIa 807T. Patients were segregated by race (white or African American) and plasma level of VWCP activity (normal or deficient). The prevalence of factor V Leiden was significantly increased among the white TM patients that had normal VWCP activity: 4 (36%) of 11 patients compared with 6 (3%) of 186 white control subjects possessed the factor V Leiden allele (P <.001; odds ratio, 17.1; 95% confidence interval, 5.4-54.0). No factor V Leiden alleles were detected in 19 white TM patients with intermediate or deficient levels of VWCP activity or in any of 12 African American patients. The prevalence of other thrombosis-associated alleles did not differ between TM patients and control subjects. These findings suggest that factor V Leiden may be a pathogenic risk factor in TM patients that have normal VWCP activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781222     DOI: 10.1182/blood.v99.2.437

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome.

Authors:  Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Lucio Lo Coco; Alessandra Malato; Rosa Di Trapani; Giorgia Saccullo; Giuseppina Pizzo; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

2.  Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients.

Authors:  Yasuko O Erickson; Noelle I Samia; Bruce Bedell; Kenneth D Friedman; Bonnie S Atkinson; Thomas J Raife
Journal:  J Clin Apher       Date:  2009       Impact factor: 2.821

Review 3.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

4.  Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis.

Authors:  Kerstin Benz; Kerstin Amann; Katalin Dittrich; Jörg Dötsch
Journal:  Pediatr Nephrol       Date:  2007-09-20       Impact factor: 3.714

5.  Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.

Authors:  Charles L Bennett; Benjamin Kim; Anaadriana Zakarija; Nicholas Bandarenko; Dilip K Pandey; Charlie G Buffie; June M McKoy; Amul D Tevar; John F Cursio; Paul R Yarnold; Hau C Kwaan; Davide De Masi; Ravindra Sarode; Thomas J Raife; Joseph E Kiss; Dennis W Raisch; Charles Davidson; J Evan Sadler; Thomas L Ortel; X Long Zheng; Seiji Kato; Masanori Matsumoto; Masahito Uemura; Yoshihiro Fujimura
Journal:  J Am Coll Cardiol       Date:  2007-09-04       Impact factor: 24.094

6.  Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.

Authors:  Thomas J Raife; Wenjing Cao; Bonnie S Atkinson; Bruce Bedell; Robert R Montgomery; Steven R Lentz; George F Johnson; X Long Zheng
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

7.  Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation.

Authors:  Seth A Levey; Randeep S Bajwa; Maria M Picken; Joseph I Clark; Kevin Barton; David J Leehey
Journal:  NDT Plus       Date:  2008-03-11

8.  De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia.

Authors:  Davide Rolla; Iris Fontana; Jean Louis Ravetti; Luigina Marsano; Diego Bellino; Laura Panaro; Francesca Ansaldo; Lisa Mathiasen; Giulia Storace; Matteo Trezzi
Journal:  J Renal Inj Prev       Date:  2015-11-30

9.  Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: a case report.

Authors:  Kostas Stylianou; George Tsirakis; Elpis Mantadakis; Irini Xylouri; Andreas Foudoulakis; Eleftheria Vardaki; Irene Katsipi; Eugene Daphnis; George Samonis
Journal:  Cases J       Date:  2009-05-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.